< Back to previous page
Researcher
Johan Maertens
- Disciplines:Biochemistry and metabolism, Microbiology, Systems biology, Laboratory medicine, Medical biochemistry and metabolism
Affiliations
- Laboratory of Clinical Microbiology (Division)
Member
From1 Oct 2014 → Today - Department of Microbiology, Immunology and Transplantation (Department)
Member
From1 Oct 2013 → 30 Sep 2014 - Woman and Child (Division)
Member
From1 Apr 2013 → 30 Sep 2013
Projects
1 - 10 of 11
- Insights in febrile neutropenia (SAFE study) and clinical and translational insights in (invasive) mold infections and mycology, with the focus on Hematologic patients.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimization and validation of collateral sensitivity based alternative treatment strategies for multidrug resistant CandidemiaFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- SAFE study: a randomized non-inferiority trialFrom1 Oct 2022 → TodayFunding: Foundations, funds and other with scientific goal
- Improving prevention and treatment strategies concerning opportunistic infections in immunocompromised hematologic patientsFrom14 Sep 2020 → TodayFunding: Foundations, funds and other with scientific goal
- Clonal evolution and biology of co-operative oncogenic events in acute lymphoblastic leukemia.From1 Oct 2018 → 30 Sep 2023Funding: Fund Recuperation Fiscal Exemption
- Fast diagnosis of opportunistic respiratory infections trough exhaled breath analysisFrom1 Oct 2017 → 30 Sep 2020Funding: FWO Applied Biomedical Research (TBM)
- Triazole-resistance in Aspergillus fumigatus: evolving epidemiology and influence on disease progression.From15 Mar 2017 → 2 Dec 2021Funding: BOF - doctoral mandates, BOF - Doctoral projects
- Faster to the fungus: rapid diagnostic and prognostic tests for invasive fungal diseasesFrom1 Aug 2016 → 9 Oct 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Rethinking 'Care after Cure' in allogeneic hematopoietic stem cell transplantation using e-Health and patient reported outcomesFrom1 Sep 2015 → 14 Nov 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Assessment of the impact of emerging azole resistance mechanisms on treatment response of invasive pulmonary aspergillosis using non-invasive imaging in experimental Aspergillus infection models.From1 Jan 2015 → 31 Dec 2018Funding: FWO research project (including WEAVE projects)
Publications
11 - 20 of 536
- Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment(2024)
Authors: Jannes Heylen, Johan Maertens, Joost Wauters
- The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey(2024)
Authors: Johan Maertens
- Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry(2024)
Authors: Johan Maertens
- Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party(2024)
Authors: Johan Maertens
- Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients(2024)
Authors: Johan Maertens
Pages: e59 - e68 - Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race(2023)
Authors: Johan Maertens
- Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings(2023)
Authors: Johan Maertens
Pages: 98 - 110 - Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party(2023)
Authors: Johan Maertens
- Conditioning Intensity in Patients Aged > 50 Years Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrom: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT(2023)
Authors: Johan Maertens
- Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON- SAKK Studies(2023)
Authors: Johan Maertens